The WW domain-containing oxidoreductase (WWOX) encodes a tumor suppressor that is frequently lost in many cancer types. Wwox-deficient mice develop normally but succumb to a lethal hypoglycemia early in life. Here, we identify WWOX as a tumor suppressor with emerging role in regulation of aerobic glycolysis. WWOX controls glycolytic genes' expression through hypoxia-inducible transcription factor 1a (HIF1a) regulation. Specifically, WWOX, via its first WW domain, physically interacts with HIF1a and modulates its levels and transactivation function. Consistent with this notion, Wwox-deficient cells exhibited increased HIF1a levels and activity and displayed increased glucose uptake. Remarkably, WWOX deficiency is associated with enhanced glycolysis and diminished mitochondrial respiration, conditions resembling the 'Warburg effect'. Furthermore, Wwoxdeficient cells are more tumorigenic and display increased levels of GLUT1 in vivo. Finally, WWOX expression is inversely correlated with GLUT1 levels in breast cancer samples highlighting WWOX as a modulator of cancer metabolism. Our studies uncover an unforeseen role for the tumor-suppressor WWOX in cancer metabolism. Cell Death and Differentiation (2014) 21, 1805-1814; doi:10.1038/cdd.2014.95; published online 11 July 2014
Furthermore, it has been reported that alteration in metabolism affects WWOX transcripts. 16 Critically, however, it is not known whether WWOX as a tumor suppressor is directly involved in the modulation of glucose metabolism.
Cancer cells exhibit several characteristics that make them tumorigenic. 17 The chronic and often uncontrolled cell proliferation that represents the essence of neoplastic disease involves not only deregulated control of cell proliferation but also corresponding adjustments of energy metabolism in order to fuel cell growth and division. 18 This metabolic adaptation is directly regulated by many oncogenes and tumor suppressors and is required to support the energetic and anabolic demands associated with cell growth and proliferation. 19 The change in glucose metabolism is the best-known example of metabolic reprogramming in cancer cells. Under aerobic conditions, normal cells process glucose, first to pyruvate via glycolysis in the cytosol and thereafter to carbon dioxide in the mitochondria; under anaerobic conditions, glycolysis is favored and relatively little pyruvate is dispatched to the oxygen-consuming mitochondria. Otto Warburg 20, 21 was the first to observe reprogramming of cancer cell energy metabolism even in the presence of oxygen; cancer cells can reprogram their glucose metabolism, and thus their energy production, by limiting their energy metabolism largely to glycolysis, leading to a state that has been termed 'aerobic glycolysis'. For example, cancer cells upregulate the hypoxia-inducible transcription factor 1a (HIF1a), which is a key mediator of this cellular adaptation to oxygen stress, 22, 23 working as a direct master transcriptional activator of many genes. On one hand, HIF1a enhances glycolytic flux by upregulating glucose transporters, notably glucose transporter 1 (GLUT1) [24] [25] [26] and by transactivating several glycolytic genes including pyruvate kinase M2 (PKM2) and hexokinase 2 (HK2). 19 On the other hand, HIF1a directly inhibits mitochondrial respiration by upregulating expression of the pyruvate dehydrogenase kinase 1 (PDK1) gene, thus leading to the high rate of glucose catabolism and lactate production. Significantly, blockage of HIF1a 22 or knockdown of either LDH-A or PDK1 inhibits tumor growth, 27 indicating their significant role in the metabolic reprogramming of cancer cells. 28 It is thus not surprising that HIF1a is tightly regulated. 29, 30 Indeed, it has been recently shown that the chromatin factor SIRT6 acts as a master regulator of glucose homeostasis via co-repressing HIF1a at glycolytic genes. 31, 32 Levels of HIF1a is also regulated at the post-transcriptional level. [33] [34] [35] Taken together, these findings demonstrate the tight regulation on HIF1a level and activity and may suggest that further mechanisms exist to ensure proper nutrient and stress response. We now present data that demonstrate that loss of tumor-suppressor WWOX is associated with enhanced level and function of HIF1a resulting in rewiring of cell metabolism and cancer transformation.
Results
WWOX deficiency causes a cell-autonomous increase in glucose uptake. As introduced, Wwox-deficient mice suffer of lethal hypoglycemia ( Figure 1a ). Although such a phenotype is typically associated with hyperinsulinemia, the mice exhibited normal pancreatic islets (Supplementary Figure S1A ) and, lower blood insulin levels (Figure 1b) , indicating that low glucose may have triggered a reduction in insulin secretion as an adaptive response. In order to determine whether WWOX influences glucose uptake in a cell-autonomous manner, we used flow cytometry to measure glucose uptake in Wwox WT and KO cells using a fluorescent glucose analog (2-NBDG) that is incorporated into cells and allows quantification of glucose uptake. Remarkably, mouse embryonic fibroblasts (MEFs) isolated from KO embryos displayed an increase in glucose uptake as early as 1 h following addition of 2-NBDG (Figure 1c ). To further demonstrate that the glucose uptake phenotype we observed is specifically due to lack of WWOX, we re-expressed WWOX in WWOX KO MEFs and tested glucose uptake. We found that indeed re-expression of WWOX reduced glucose uptake in KO MEFs (Figure 1d ). These results indicate that WWOX deficiency causes increased glucose uptake in a cell-autonomous manner.
WWOX deficiency is associated with enhanced glycolysis and reduced mitochondrial respiration. The glucose uptake results prompted us to test how glucose is utilized in Wwox-deficient cells. We first measured lactate production, in order to determine whether glycolysis was enhanced. We found that Wwox-deficient cells displayed significantly higher levels of lactate when compared with WT cells, as assessed in medium of growing MEFs (Figure 2a) . Similarly, Wwox-deficient mice displayed significantly higher serum levels of lactate when compared with WT mice (Supplementary Figure S2A) . Concomitantly, lack of WWOX causes a reduction in oxygen consumption (Figure 2b ), suggesting that in Wwox-deficient cells glucose is utilized primarily for glycolysis, whereas mitochondrial respiration is inhibited. To further validate these results, we measured levels of ATP, the final product of mitochondrial respiration. We found that Wwox-deficient MEFs contain lower ATP levels as compared with WT cells (Figure 2c ). Moreover, we checked nicotinamide adenine dinucleotide (NADH) levels as a main indicator for tricarboxylic acid cycle (TCA cycle) activity using flow cytometry. Interestingly, Wwox-deficient MEFs contained significant lower levels of NADH as compared with WT cells (Figure 2d ). Furthermore, we checked nicotinamide adenine dinucleotide phosphate (NADPH) as an indicator for enhanced glycolysis and found that Wwox-deficient MEFs and livers accumulate a higher NADPH levels, although less significant as compared with changes in NADH levels, as compared with WT (Figures 2e, Supplementary Figure S2B ). This mild increase in NADPH levels in KO could be attributed to NADPH reduced utilization in reactive oxygen species neutralization 14 and in building lipids and fatty acids (unpublished data). To further validate the observed shift to glycolysis, we used the Metabolon Inc. platform to assess levels of metabolites in WT and KO MEFs. Interestingly, Wwox-deficient MEFs displayed higher levels of fructose 1,6 diphosphate, the glycolytic intermediate, and reduced levels of the TCA cycle intermediates fumarate, malate and succinate (Figure 2f) Figure S3B) , many of the glycolytic genes were upregulated in Wwox KO cells (Supplementary Figure S3A) . The highest difference was observed among key glycolytic genes, such as triose phosphate isomerase (Tpi), aldolase, and the ratelimiting glycolytic enzyme phosphofructokinase-1 (Pfk-1) (Supplementary Figure S3A) . Interestingly, all of these upregulated key glycolytic genes in the superarray were HIF1a target genes (red bars; Supplementary Figure S3B) . We also observed a mild change in the pentose phosphate pathway (Supplementary Figure S3C) or gluconeogenesis pathway (Supplementary Figure S3D) . Of note, levels of gluconeogenesis genes in the liver of KO mice were elevated (Supplementary Figure S3E) , likely due to physiological response to increased serum lactate (Supplementary Figure  S2A) but this change seems not enough to rescue the hypoglycemic phenotype in Wwox KO mice. As HIF1a is a master regulator gene of glycolysis, we performed quantitative real-time PCR (qRT-PCR) for other key glycolytic genes that are HIF1a target genes and not presented in the superarray platform. Using RT-PCR, we validated increased expression of numerous HIF1a target genes in Wwox-KO cells as compared with WT cells using an independent RNA samples ( Figure 3a) . Notably, we observed higher levels of Pdk1, which phosphorylates and inhibits pyruvate dehydrogenase, the rate-limiting enzyme that regulates entrance of pyruvate into the TCA cycle. Importantly, we found that overexpression of intact WWOX, but not a mutant form of WWOX-WFPA, which harbor a mutation in WW1 domain of WWOX that abrogates its interaction ability, in Wwox KO MEFs reduced HIF1a target genes' expression under normoxia, as assessed by qRT-PCR (Figure 3b ). To further validate that this phenotype is not limited to MEFs, we examined the effect of WWOX depletion in MCF7 breast cancer cells. As shown in Supplementary Fig S4A, WWOX knockdown in MCF7 cells is associated with upregulation of HIF1a glycolytic genes. In the same line, WWOX overexpression in WWOX-depleted MCF7 breast cancer cells suppressed HIF1a target genes (Supplementary Figure S4B) .
Increased expression of HIF1a target genes was also observed in vivo using RNA from murine peripheral organs including brown adipose tissue (BAT) (Figure 3c ) and skeletal muscles (Figure 3d ). In brief, our results indicate that in the absence of WWOX, expression of multiple glucose-related genes are upregulated, particularly HIF1a target genes, causing enhanced glycolysis and, in parallel, inhibition of mitochondrial respiration. 
HIF1 target genes expression (skeletal muscle) Figure S4D) . These results further suggest that WWOX modulates HIF1a transactivation function.
HIF1 target genes expression (BAT)
WWOX decreases HIF1a protein levels both in vitro and in vivo. Conditions of oxygen stress cause activation of HIF1a, with increased protein levels because of both protein synthesis and stabilization of the protein. 36 As lack of WWOX mimic an oxygen stress response, we set to determine whether Wwox-deficient cells exhibit increased protein levels of HIF1a. Initially, we tested whether WWOX expression affect mRNA levels of HIF1a. As shown in Supplementary Figure S4C , HIF1a mRNA levels are comparable between Wwox KO and WT skeletal muscles. Next, we examined whether protein levels of HIF1a is different between Wwox KO and WT tissues and cells. Nuclei of Wwox WT and KO MEFs grown under normoxic conditions were separated and immunoblot analysis was performed with an antibody specific for HIF1a. As expected for a normoxic condition, HIF1a was barely detected in WT cells (Figure 3e ). In contrast, HIF1a was readily detected in Wwox KO cells (Figure 3e ). HIF1a was also detected in skeletal muscles, which is considered the main peripheral organ involved in glucose uptake, of Wwox KO mice (Figure 3f ). These results strongly indicate that under normal oxygen conditions, WWOX has an important inhibitory role on HIF1a-dependent glucose-related gene transcription, and lack of WWOX is sufficient to upregulate glycolytic gene transcription.
WWOX is downregulated under hypoxic conditions. Our findings so far indicate that WWOX deficiency is associated with increased levels of HIF1a protein and its target genes in normoxic conditions. These results promoted us to examine the effect of hypoxia, when HIF1a protein is stabilized, on WWOX levels. In agreement with recent findings, 16 we found that WWOX is downregulated under hypoxic conditions (Figure 4a ) or following CoCl 2 treatment (Figure 4b ), which mimics hypoxic conditions. This led us to wonder on the significance of WWOX expression on HIF1a levels under hypoxic conditions. To do so, we determined the levels of HIF1a protein in WT and KO MEFs under hypoxic conditions. Interestingly, we found that WWOX does not affect HIF1a protein levels under hypoxic conditions (Figure 4c ), likely as WWOX levels goes down under these conditions. On the contrary, when WWOX is overexpressed in WT MEFs under hypoxic conditions, levels of HIF1a target genes are suppressed (Figure 4e ), unlike the situation in normoxic conditions (Figure 4d indicate that WWOX regulates HIF1a levels and activity under physiological conditions.
Knocking down HIF1a completely rescues the metabolic phenotype in vitro and in vivo. The above results suggest that lack of WWOX triggers a HIF1a-dependent metabolic switch. In order to test whether HIF1a has a critical role in this phenotype, we decided to knockdown HIF1a in WWOX KO cells and test whether we could rescue the metabolic abnormalities observed in these cells. For this purpose, we specifically knocked down HIF1a in Wwox-deficient cells (Figure 5a) . Notably, when HIF1a levels were depleted, the increased glucose uptake was completely rescued in KO-MEFs (Figure 5b ), and to a lesser extent in WT-MEFs (Supplementary Figure S5A) . Importantly, forced expression of WWOX in WT cells did not affect glucose uptake (Supplementary Figure S5A) . To test whether the phenotypes observed in the Wwoxdeficient mice was dependent on HIF1a, as we found in vitro, we treated Wwox-deficient mice with digoxin. Digoxin is known as an inhibitor for HIF1a expression and blocker for number of cancer types. [37] [38] [39] [40] Strikingly, treatment with digoxin caused a fast and specific increase in blood glucose levels specifically in KO mice (Figure 5c ). Consistently, treated KO mice displayed decrease expression of HIF1a target genes, namely GLUT1 and prolyl-hydroxylase domain 3 (PHD3) (Supplementary Figure S5B) , while WT mice did not show any decrease in the levels of these genes (Supplementary Figure  S5C) . These results indicate that, similar to what we observed in KO MEFs, regulation of glucose metabolism by WWOX depends on HIF1a in vivo as well.
WWOX physically interacts with HIF1a and functionally affects its level. WWOX interacts with multiple proteins mainly via its WW1 domain.
13,14 Therefore, we set to examine whether WWOX interacts with HIF1a and inhibits its function. To do so, we took advantage of mammalian glutathione S-transferase (GST)-fusions expressing truncated 
PBS (dilution solution) was injected as control. (KO ¼ 3, WT ¼ 3). (d) WWOX physically interacts with
HIF1a. 293T cells were transfected with GST-WWOX or GST-WWOX-WFPA (mutation in WW1 of the WWOX in its interaction site). At 24-h post-transfection, 1 mM of MG-132 was added for an additional 4 h to stabilize HIF1a, and then cytoplasm/nucleus subfractionation was done followed by GST pulldown. (e) Endogenous WWOX physically interacts with endogenous HIF1a. HEK293T cells were treated with MG-132 (1 mM) for 4 h to stabilize HIF1a followed by immunoprecipitation (IP) with anti-WWOX antibody.
Immunoblotting was done using anti-WWOX and anti-HIF1a antibodies. Anti-IgG was used as a negative control for IP. (f) Proteins were extracted from WWOX WT and KO MEFs after adding 1 mM MG132 (a pan inhibitor of the proteasome) for 4 h. Immunoblotting was done using anti-WWOX and anti-hydroxylated HIF1a antibodies. TUBULIN was used as a loading control. Graph on right shows densitometry analysis domains of WWOX. 14, 41 These fusions were expressed separately in HEK293 cells followed by GST pulldown. As seen in Supplementary Figure S6A , only GST-WW1 domaincontaining vectors were able to precipitate HIF1a. We next examined whether full-length mammalian GST-WWOX or GST-WWOX-WFPA are capable of interacting with HIF1a. Expression of these constructs in HEK293 cells followed by GST pulldown revealed that WWOX, but no WFPA mutant, is able to associate with HIF1a (Figure 5d ). To validate that WWOX and HIF1a interact under physiological conditions, we examined endogenous protein interaction. HEK293 cells were treated with MG132 followed by immunoprecipitation. As seen in Figure 5e and Supplementary Figure 6SA , endogenous specific interaction can be detected between WWOX and HIF1a. To further examine functional relevance of WW1 domain interaction with HIF1a, we re-expressed WWOX or WWOX-WFPA in Wwox-KO MEFs, then nucleus/ cytoplasm subfractionation and glucose uptake was performed. Enforced WWOX expression, but not that of mutant WWOX-WFPA, was able to decrease HIF1a levels comparable to HIF1a-depleted cells (Figure 5a ), and to rescue glucose uptake (Figure 5b ) and expression of HIF1a target genes (Figure 3b) .
It is known that under normoxia, HIF1a is hydroxylated (HIF1a-OH) at multiple prolyl residues by the PHD proteins. Following hydroxylation, HIF1a is recognized by von HippelLindau (VHL) ubiquitin E3 ligase, marking HIF1a for subsequent proteasome degradation. Using specific antibodies, we found that HIF1a hydroxylation is significantly reduced in WWOX KO MEFs as compared with WWOX WT MEFs (Figure 5f ), suggesting that WWOX increases HIF1a hydroxylation leading to its degradation under normoxia. These results promoted us to examine whether WWOX interacts with HIF1a-OH. HEK293 cells were treated with MG-132 (to inhibit HIF1a proteasomal degradation) or cultured in hypoxic conditions. Endogenous proteins were immunoprecipitated using monoclonal anti-WWOX or anti-HIF1a antibody and complexes were immunoblotted using anti-HIF1a or anti-WWOX or anti-HIF1a-OH antibody. As shown in Supplementary Figure S6A , WWOX association with HIF1a or HIF1a-OH is mainly observed on addition of MG-132 suggesting that WWOX expression renders HIF1a less stable. Altogether, these results suggest that WWOX interaction with HIF1a modulates HIF1a levels and inhibits its function.
WWOX-deficient cells are more tumorigenic and dependent on HIF1a. WWOX is known as a tumor suppressor that is altered in many cancer types. 3, 42, 43 In light of our findings that WWOX controls glycolysis through HIF1a, we hypothesized that loss of WWOX is associated with increased HIF1a levels and tumorigenicity. To check this possibility, we generated MEFs from WWOX WT and KO embryos and immortalized them using a standard 3T3 protocol followed by H-RAS transformation. Notably, during transformation, lower numbers of WT MEF-3T3 cell lines were transformed as compared with KO MEF-3T3 cells, with longer time (data not shown). We next injected transformed WWOX WT and KO MEFs subcutaneously into flanks of NOD/SCID mice to assess their tumorigenicity in vivo. KO MEFs grew at a higher rate as compared with WT cells (Figure 6a) , with higher final tumors volume and weight (Figures 6b and c) . Re-expression of WWOX, but not WWOX-WFPA, in KO cells rescued tumor growth. Interestingly, when HIF1a was knocked down in KO transformed cells, the tumorigenic phenotype was abolished. In contrast, depletion of HIF1a in WT transformed cells did not have a potent effect on tumor growth as in KO cells suggesting that KO cells are more dependent on HIF1a for their growth.
Consistent with these and earlier results, WWOX KO tumors demonstrated elevated levels of GLUT1, a HIF1a target gene, as compared with WT tumors, providing evidence of enhanced aerobic glycolysis in these tumors (Figure 6d ).
Inverse correlation between WWOX and GLUT1 in human cancer. Finally, we examined whether human tumors display an inverse correlation between expression of WWOX and GLUT1, using immunohistochemistry. To do so, a breast tissue microarray (US Biomax, Rockville, MD, USA) was immunostained with anti-WWOX or anti-GLUT1 antibody and levels of WWOX and GLUT1 was scored. Intriguingly, we observed a significant inverse correlation (Po0.05) between WWOX and GLUT1 levels in these tumors (Figure 6e ). Together, these results support our hypothesis that the tumor-suppressor WWOX functions as a modulator of cancer metabolism.
Discussion
Previous characterization of targeted deletion of the Wwox gene in mice revealed its bona fide tumor-suppressor function. 4, 8, 11 However, it is not well known how loss of WWOX facilitates tumor formation. We present data here which reveal for the first time a role of WWOX in controlling cell metabolism, through inhibition of aerobic glycolysis. Under conditions of normal oxygen availability, WWOX represses expression of key enzymes, diverting pyruvate toward the mitochondrial TCA cycle for efficient ATP production. Our data demonstrate that WWOX interacts with HIF1a; on one hand WWOX causes suppression of HIF1a transactivation function and on the other WWOX expression is associated with HIF1a hydroxylation and likely its degradation to maintain proper glucose flux toward mitochondrial respiration and to prevent excessive glycolysis. Several evidences support this model. First, Wwox-deficient mice suffer from severe hypoglycemia leading to mice mortality at 3-4 weeks of age with high levels of serum lactate. In addition, Wwox-deficient cells display higher glucose uptake with low oxygen consumption and ATP production as well as an increase in glycolytic genes expression when compared with WT cells. These findings suggest that WWOX deficiency shifts glucose metabolism toward glycolysis, even under normoxic conditions (Warburg effect). Second, WWOX decreases HIF1a levels and inhibits its transactivation function. WWOX physically interacts with HIF1a and functionally reduces its levels. Furthermore, WWOX-sufficient cells display higher HIF1a hydroxylation as compared with WWOX-deficient cells. After all, WWOX suppresses glycolysis through HIF1a inhibition. In the absence of WWOX, the glycolytic phenotype can be rescued either through knocking down HIF1a in Wwox-deficient cells, or inhibiting HIF1a in Wwox-deficient mice by HIF1a inhibitor, digoxin. Third, loss of WWOX in transformed MEFs is associated with enhanced tumorigenesis as compared with WT ones. Notably, Wwox-deficient cells depleted of HIF1a failed to form tumors in mice. Importantly, expression of WWOX is inversely correlated with that of GLUT1, a direct target of HIF1a, in human breast cancer patients. Thus, it is likely that the tumor-suppressor WWOX acts as a safeguard mechanism to inhibit HIF1a activity under normoxic conditions, to guarantee glucose flux into mitochondria and TCA cycle and so prevent Warburg effect.
How does tumor-suppressor WWOX affect glucose metabolism? Our findings demonstrate that WWOX affects HIF1a function. In this context, there are two supposed scenarios for HIF1a regulation by WWOX. The first possibility is that WWOX interacts with HIF1a and inhibits its transactivation function; this could be through sequestering HIF1a and prevented it from binding its targets' promoters. In addition, WWOX could interact with HIF1a and limits its localization in the nucleus or on its HRE consensus sequence, thus inhibiting its activity, perhaps similar to TSG10. 44 Alternatively, WWOX could interact with HIF1a and facilitate its degradation. When WWOX is lost or is unable to interact with HIF1a, HIF1a accumulates. Eventually, association between WWOX and HIF1a is required for HIF1a neutralization in normoxic conditions. HIF1a degradation under normoxic conditions happened mainly by PHD2 that hydroxylates it and then HIF1a is ubiquitinated by VHL ubiquitin E3 ligase marking HIF1a for subsequent proteasome degradation. Intriguingly, HIF1a is hydroxylated progressively in WWOX WT MEFs compared with modest HIF1a hydroxylation in WWOX KO MEFs suggesting that WWOX facilitates HIF1a hydroxylation and perhaps HIF1a degradation under normoxic conditions. Moreover, this can explain the observed reduction of WWOX levels under hypoxic conditions, which may contribute to HIF1a stabilization. Similarly, it has been reported that PHD2 interaction with HIF1a in the nucleus is crucial for HIF1a hydroxylation and degradation. 46 In clinical samples, HIF is found elevated and correlates with poor patient prognosis in a variety of cancers. As WWOX is frequently lost in cancer, this may be associated with increased levels of HIF1a (Figure 6f) . In this scenario, HIF1a target genes, including GLUT1, HK2 and PDK1, are transcribed resulting in their enhanced transactivation. Enhanced expression of these genes correlates with enhanced glycolysis, while decreased glucose flux into TCA cycle and oxidation phosphorylation, namely Warburg effect. Importantly, high activity of these factors has been widely associated with tumor development and metastasis. 47, 48 It is therefore possible that WWOX loss leads to dysregulation of key glycolytic genes that fuel cancer cell metabolism, an emerging hallmark of cancer cells. In conclusion, we demonstrate evidence that WWOX can modulate cancer cell metabolism through regulation of HIF1a level and activity.
Materials and Methods
Cell culture and transient transfection. MEF cells were grown in DMEM; MCF7 and HEK293 cells were grown in RPMI, both medium were supplemented with 10% FBS (Gibco, Grand Island, NY, USA), glutamine and penicillin/streptomycin (Biological Industries, Beit-Haemek, Israel). Cells were routinely authenticated, and cell aliquots from early passages were used. Transient transfections were achieved using Mirus TransLTi (Mirus Bio LLC, Madison, WI, USA) according to the manufacturer.
RNA extraction and reverse transcription-PCR and RT-PCR.
Total RNA was prepared using TRI reagent (Sigma Aldrich, Munich, Germany) as described by the manufacturer. One microgram of RNA was used for cDNA synthesis using First-Strand cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). All measurements were performed in triplicate and standardized to the levels of UBC. Cellular fractionation. Nuclear and cytoplasmic extracts were prepared as follows. First, cells were scraped in PBS, and after centrifugation, the cell pellet was reconstituted in a hypotonic lysis buffer (10 mmol/l HEPES (pH 7.9), 10 mmol/l KCl, 0.1 mmol/l EDTA) supplemented with 1 mmol/l DTT and a broad-spectrum cocktail of protease inhibitors (Sigma-Aldrich, Munich, Germany). The cells were allowed to swell on ice for 15 min, then NP40 was added and cells were lysed by vortex. After centrifugation, the cytoplasmic fraction was collected. Afterward, nuclear extracts were obtained by incubating nuclei in a hypertonic nuclear extraction buffer (20 mmol/l HEPES (pH 7.9), 0.42 mol/l KCl, 1 mmol/l EDTA) supplemented with 1 mmol/l DTT for 15 min at 4 1C. The nuclear fraction was collected after centrifugation. Successful fractionation was confirmed by the exclusive presence of GAPDH and lamin in the cytoplasmic and nuclear fractions, respectively.
Immunoprecipitation assays. Cells were lysed by using Nonidet P-40 lysis buffer containing 50 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 10% glycerol, 0.5% Nonidet P-40 and protease inhibitors. Lysates were pre-cleared with mouse IgG, immunoprecipitations were carried out in the same buffer and lysates were washed four times with the same buffer containing 0.1% Nonidet P-40. Immunoblotting was conducted under standard conditions. Antibodies used were polyclonal anti-WWOX, polyclonal anti-Lamin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-hydroxy HIF1a rabbit (Pro564) rabbit (cat # 3434, Cell Signaling Technology, Danvers, MA, USA) and anti-HIF1a mouse mAB (cat # NB100-105, Novous Biological, Littleton, CO, USA).
GST pulldown. HEK293 cells were transfected with expression vectors encoding mammalian GST-WWOX (pEBG-WWOX) and GST-WWOX-WFPA (where tryptophan (W44) and proline (P47) in the first WW domain of WWOX was replaced by phenylalanin (F) and alanine (A), respectively). Twenty-four hours later, cells were exposed to hypoxia (1% O 2 for 6 h) and then lysed using 0.5% NP40-containing buffer. Following washing, cells were incubated with GST beads (Amersham GE Healthcare, Chicago, IL, USA) for 4 h at 4 1C, washed and then prepared for electrophoresis.
Lactate and oxygen consumption assays. Lactate levels were determined with Lactate Assay Kit (BioVision, Milpitas, CA, USA). Optical density (OD) was measured at 570 nm, 30 min after addition of substrate. For oxygen consumption, Wwox-WT and KO MEFs (5 Â 10 4 ) were seeded. At 24 h, oxygen consumption rate was measured with the Seahorse XF24 instrument (Seahorse Bioscience, North Billerica, MA, USA), as per the producer's instructions.
Glucose uptake assay. Cells were grown under normal conditions for 24 h and 4 mM 2-NBDG (Invitrogen, Paisley, UK) was added to the media for 1 h. Fluorescence was quantified using flow cytometry (BD, Franklin Lakes, NJ, USA).
ATP concentration assay. Wwox-WT or KO MEFs were grown in normal media for 24 h and ATP concentration was measured by ATP bioluminescent somatic cell assay kit (Sigma-Aldrich) as per the manufacturer's instructions.
NADPH assay. NADPH concentration was determined with the NADPH Assay Kit (BioVision). OD was measured at 450 nm from liver lysates as per the manufacturer's instructions.
Luciferase reporter assays. 293T (1 Â 10 5 ) cells were transiently transfected with 1 mg of the following plasmids as described in the text: HIF-Luc, 2MYC-EV, 2MYC-WWOX, HA-HIF1a and Renilla. Twenty-four hours after transfection, cells were incubated under normoxia or hypoxia (1% O 2 ) for 6 h after which cells were harvested and luciferase activity was determined using the Dual Luciferase Reporter Assay system (Promega, Madison, WI, USA).
